GlassScriptPhysician profile
Alison Z Young
NPI 1891734893
$53,231.97
in general payments reported to CMS, 2019-2025
38 companies · $5,877 in 2025
The $5,877 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,526 · 2020: $1,755 · 2021: $5,931 · 2022: $8,323 · 2023: $8,789 · 2024: $19K · 2025: $5,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $17K · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,968.19 |
| Consulting Fee | $16,516.20 |
| Education | $212.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $7,265.78 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $5,848.52 | 2021-2025 | Opzelura |
| Abbvie INC. | $5,811.36 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Janssen Biotech, INC. | $4,412.66 | 2019-2025 | Tremfya, Remicade, Stelara |
| E.R. Squibb & Sons, L.L.C. | $4,006.07 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $3,530.53 | 2019-2025 | Winlevi, Absorica Ld, Levulan Kerastick |
| Dermavant Sciences, INC. | $3,390.25 | 2023-2024 | Vtama |
| Biofrontera INC. | $2,911.58 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $2,244.93 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,862.57 | 2019-2025 | |
| Pfizer INC. | $1,688.31 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,402.38 | 2023-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,380.05 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,258.85 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Merz North America, INC. | $1,051.14 | 2023-2025 | Xeomin |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.